8659 related articles for article (PubMed ID: 23000897)
21. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
22. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
Lopez G; Costanza J; Colleoni M; Fontana L; Ferrero S; Miozzo M; Fusco N
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691046
[TBL] [Abstract][Full Text] [Related]
23. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
24. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
[TBL] [Abstract][Full Text] [Related]
25. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM
BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546
[TBL] [Abstract][Full Text] [Related]
26. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
[TBL] [Abstract][Full Text] [Related]
27. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Curtis C; Shah SP; Chin SF; Turashvili G; Rueda OM; Dunning MJ; Speed D; Lynch AG; Samarajiwa S; Yuan Y; Gräf S; Ha G; Haffari G; Bashashati A; Russell R; McKinney S; ; Langerød A; Green A; Provenzano E; Wishart G; Pinder S; Watson P; Markowetz F; Murphy L; Ellis I; Purushotham A; Børresen-Dale AL; Brenton JD; Tavaré S; Caldas C; Aparicio S
Nature; 2012 Apr; 486(7403):346-52. PubMed ID: 22522925
[TBL] [Abstract][Full Text] [Related]
28. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
[TBL] [Abstract][Full Text] [Related]
29. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
30. Mutational landscape differences between young-onset and older-onset breast cancer patients.
Mealey NE; O'Sullivan DE; Pader J; Ruan Y; Wang E; Quan ML; Brenner DR
BMC Cancer; 2020 Mar; 20(1):212. PubMed ID: 32164620
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.
Sandhu R; Rivenbark AG; Mackler RM; Livasy CA; Coleman WB
Int J Oncol; 2014 Feb; 44(2):563-72. PubMed ID: 24297604
[TBL] [Abstract][Full Text] [Related]
32. Subtypes of familial breast tumours revealed by expression and copy number profiling.
Waddell N; Arnold J; Cocciardi S; da Silva L; Marsh A; Riley J; Johnstone CN; Orloff M; Assie G; Eng C; Reid L; Keith P; Yan M; Fox S; Devilee P; Godwin AK; Hogervorst FB; Couch F; ; Grimmond S; Flanagan JM; Khanna K; Simpson PT; Lakhani SR; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Oct; 123(3):661-77. PubMed ID: 19960244
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
[TBL] [Abstract][Full Text] [Related]
34. Integrated genomic analyses of ovarian carcinoma.
Cancer Genome Atlas Research Network
Nature; 2011 Jun; 474(7353):609-15. PubMed ID: 21720365
[TBL] [Abstract][Full Text] [Related]
35. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
36. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
37. Whole-genome analysis informs breast cancer response to aromatase inhibition.
Ellis MJ; Ding L; Shen D; Luo J; Suman VJ; Wallis JW; Van Tine BA; Hoog J; Goiffon RJ; Goldstein TC; Ng S; Lin L; Crowder R; Snider J; Ballman K; Weber J; Chen K; Koboldt DC; Kandoth C; Schierding WS; McMichael JF; Miller CA; Lu C; Harris CC; McLellan MD; Wendl MC; DeSchryver K; Allred DC; Esserman L; Unzeitig G; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Leitch M; Hunt K; Olson J; Tao Y; Maher CA; Fulton LL; Fulton RS; Harrison M; Oberkfell B; Du F; Demeter R; Vickery TL; Elhammali A; Piwnica-Worms H; McDonald S; Watson M; Dooling DJ; Ota D; Chang LW; Bose R; Ley TJ; Piwnica-Worms D; Stuart JM; Wilson RK; Mardis ER
Nature; 2012 Jun; 486(7403):353-60. PubMed ID: 22722193
[TBL] [Abstract][Full Text] [Related]
38. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
40. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
